(Q38464989)

English

Absolute lymphocyte count at day + 21 predicts survival in patients with early-stage diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, adriamycin, vincristine and prednisone

scientific article published on 19 April 2012

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

Absolute lymphocyte count at day + 21 predicts survival in patients with early-stage diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, adriamycin, vincristine and prednisone (English)

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

B-cell lymphoma

1 reference

based on heuristic

inferred from title

diffuse large B-cell lymphoma

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Yee Soo Chae

1

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

Hocheol Shin

2

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

Sang Kyun Sohn

3

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

Soo Jung Lee

4

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

Joon Ho Moon

5

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

Byung Woog Kang

6

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

Jong Gwang Kim

7

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

Deok-Hwan Yang

8

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

Je-Jung Lee

9

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

Tae In Park

10

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

publication date

19 April 2012

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

Leukemia & Lymphoma

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

53

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

9

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

1757-1763

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.670231

21 January 2018

Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.670231

21 January 2018

CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.670231

21 January 2018

Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.670231

21 January 2018

The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.670231

21 January 2018

Lymphotoxin alfa and receptor-interacting protein kinase 1 gene polymorphisms may correlate with prognosis in patients with diffuse large B cell lymphoma treated with R-CHOP.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.670231

21 January 2018

Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.670231

21 January 2018

Lymphocytopenia as a prognostic marker for diffuse large B cell lymphomas.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.670231

21 January 2018

Low absolute lymphocyte count is a poor prognostic factor in diffuse-large-B-cell-lymphoma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.670231

21 January 2018

Low absolute lymphocyte count is a poor prognostic marker in patients with diffuse large B-cell lymphoma and suggests patients' survival benefit from rituximab

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.670231

21 January 2018

Influence of low absolute lymphocyte count of patients with nongerminal center type diffuse large B-cell lymphoma with R-CHOP therapy

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.670231

21 January 2018

Revised response criteria for malignant lymphoma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.670231

21 January 2018

Lymphocyte recovery as a positive predictor of prolonged survival after autologous peripheral blood stem cell transplantation in T-cell non-Hodgkin's lymphoma.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.670231

21 January 2018

Prognostic significance of platelet recovery pattern after allogeneic HLA-identical sibling transplantation and its association with severe acute GVHD.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.670231

21 January 2018

Early lymphocyte recovery following autologous peripheral stem cell transplantation is associated with better survival in younger patients with lymphoproliferative disorders.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.670231

21 January 2018

Early lymphocyte recovery predicts superior survival after autologous stem cell transplantation in non-Hodgkin lymphoma: a prospective study

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.670231

21 January 2018

FcgammaRIIa polymorphism and clinical response to rituximab in non-Hodgkin lymphoma patients.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.670231

21 January 2018

Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.670231

21 January 2018

Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.670231

21 January 2018

Absolute lymphocyte count recovery after induction chemotherapy predicts superior survival in acute myelogenous leukemia

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.670231

21 January 2018

Identifiers

10.3109/10428194.2012.670231

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38464989&oldid=1760944749"